Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary

  Ovarian Neoplasms

  Free Subscription


1 Am J Obstet Gynecol
7 Ann Oncol
1 Br J Cancer
3 Gynecol Oncol
6 Int J Gynecol Pathol
1 J Clin Oncol
1 Oncogene
2 Oncol Rep
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Obstet Gynecol

  1. HERMENS M, van Altena AM, Nieboer TE, Schoot BC, et al
    Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis. The ENOCA population-based cohort study.
    Am J Obstet Gynecol. 2020 Jan 22. pii: S0002-9378(20)30062.
    PubMed     Text format     Abstract available

    Ann Oncol

  2. LIU JF, Barry WT, Birrer M, Lee JM, et al
    Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Ann Oncol. 2019;30:551-557.
    PubMed     Text format     Abstract available

  3. COLOMBO N, Sessa C, du Bois A, Ledermann J, et al
    ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
    Ann Oncol. 2019;30:672-705.
    PubMed     Text format     Abstract available

  4. BUECHEL M, Herzog TJ, Westin SN, Coleman RL, et al
    Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
    Ann Oncol. 2019;30:721-732.
    PubMed     Text format     Abstract available

  5. JOLY F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, et al
    Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
    Ann Oncol. 2019;30:845-852.
    PubMed     Text format     Abstract available

  6. GAILLARD SL, Coleman RL
    Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
    Ann Oncol. 2019;30:1025-1028.
    PubMed     Text format    

  7. MATULONIS UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
    Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
    Ann Oncol. 2019;30:1080-1087.
    PubMed     Text format     Abstract available

  8. HUANG T, Tworoger SS, Willett WC, Stampfer MJ, et al
    Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
    Ann Oncol. 2019;30:303-309.
    PubMed     Text format     Abstract available

    Br J Cancer

  9. HASEGAWA K, Shimada M, Takeuchi S, Fujiwara H, et al
    A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
    Br J Cancer. 2020 Jan 31. pii: 10.1038/s41416-020-0734.
    PubMed     Text format     Abstract available

    Gynecol Oncol

  10. FEKETE JT, Osz A, Pete I, Nagy GR, et al
    Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30006.
    PubMed     Text format     Abstract available

  11. HAVRILESKY LJ, Lim S, Ehrisman JA, Lorenzo A, et al
    Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
    Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070.
    PubMed     Text format     Abstract available

  12. XUE C, Xu Y, Ye W, Xie Q, et al
    Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
    Gynecol Oncol. 2020 Jan 24. pii: S0090-8258(19)31804.
    PubMed     Text format     Abstract available

    Int J Gynecol Pathol

  13. XING D, Berrebi AA, Liu C, Richmond A, et al
    An Epithelioid Smooth Muscle Neoplasm Mimicking a Signet Ring Cell Carcinoma in the Ovary.
    Int J Gynecol Pathol. 2019;38:464-469.
    PubMed     Text format     Abstract available

  14. CHOI YJ, Ho J, Yoo J, Liu J, et al
    Next-generation Sequencing of an Ovarian Spindle Cell Tumor Identified an Ovarian Low-grade Endometrial Stromal Sarcoma: A Rare Entity.
    Int J Gynecol Pathol. 2019;38:474-478.
    PubMed     Text format     Abstract available

  15. HUSSAIN I, Howard RS, Syed V, Allgauer M, et al
    A Cell Line-based Immunohistochemical p53 Expression Pattern Control Panel.
    Int J Gynecol Pathol. 2019;38:449-458.
    PubMed     Text format     Abstract available

  16. LI YP, Chang K, Chen TW, Lee SP, et al
    Primary Ewing Family of Tumor Arising in the Ovary: A Case Report.
    Int J Gynecol Pathol. 2019;38:470-473.
    PubMed     Text format     Abstract available

  17. KOH NWC, Seow WY, Lee YT, Lam JCM, et al
    Pericytoma With t(7;12): The First Ovarian Case Reported and a Review of the Literature.
    Int J Gynecol Pathol. 2019;38:479-484.
    PubMed     Text format     Abstract available

  18. MA Q, Yuan Y, Wang Y, Shao C, et al
    Misdiagnosis of High-grade Serous Ovarian Cancer With BRCA Mutation as Endometriotic Cyst Due to Its Unique Gross Morphology: A Case Report and Literature Review.
    Int J Gynecol Pathol. 2020 Jan 23. doi: 10.1097/PGP.0000000000000663.
    PubMed     Text format     Abstract available

    J Clin Oncol

  19. KONSTANTINOPOULOS PA, Norquist B, Lacchetti C, Armstrong D, et al
    Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Jan 27:JCO1902960. doi: 10.1200/JCO.19.02960.
    PubMed     Text format     Abstract available


  20. KLEINSCHMIDT EG, Miller NLG, Ozmadenci D, Tancioni I, et al
    Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.
    Oncogene. 2019 Jul 15. pii: 10.1038/s41388-019-0881.
    PubMed     Text format     Abstract available

    Oncol Rep

  21. ISHIKURA N, Yorozu K, Kurasawa M, Yanagisawa M, et al
    Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
    Oncol Rep. 2019;42:1057-1065.
    PubMed     Text format     Abstract available

  22. VACLAVIKOVA R, Klajic J, Brynychova V, Elsnerova K, et al
    Development of highresolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
    Oncol Rep. 2019;42:763-774.
    PubMed     Text format     Abstract available

    PLoS One

  23. AYYAGARI VN, Wang X, Diaz-Sylvester PL, Groesch K, et al
    Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression-An in vitro study.
    PLoS One. 2020;15:e0228024.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.